Comparison 3. Oral (single dose) vs. intramuscular vitamin K.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 PIVKA II present	4		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
1.1 At 1‐7 days	3	119	Risk Ratio (M‐H, Fixed, 95% CI)	1.02 [0.60, 1.76]
1.2 At 2 weeks	1	285	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.3 At 1 month	2	279	Risk Ratio (M‐H, Fixed, 95% CI)	2.82 [0.30, 26.78]
1.4 At 3 months	1	131	Risk Ratio (M‐H, Fixed, 95% CI)	0.81 [0.31, 2.11]
2 PIVKA II levels	1	220	Mean Difference (IV, Fixed, 95% CI)	0.0 [‐0.00, 0.00]
2.1 At 1‐7 days	1	220	Mean Difference (IV, Fixed, 95% CI)	0.0 [‐0.00, 0.00]
3 Plasma vitamin K1 (ng/ml)	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
3.1 At 1‐7 days	1	19	Mean Difference (IV, Fixed, 95% CI)	36.89 [‐48.21, 121.99]
3.2 At 2 weeks	1	138	Mean Difference (IV, Fixed, 95% CI)	‐0.79 [‐1.02, ‐0.56]
3.3 At 1 month	2	200	Mean Difference (IV, Fixed, 95% CI)	‐0.23 [‐0.30, ‐0.16]
3.4 At 3 months	1	119	Mean Difference (IV, Fixed, 95% CI)	‐0.06 [‐0.12, 0.00]
4 Prolonged prothrombin time (>1.5 normal)	1	52	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.1 At 1‐7 days	1	52	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
5 Prothrombin antigen	1	259	Mean Difference (IV, Fixed, 95% CI)	0.0 [‐0.04, 0.04]
5.1 At 1‐7 days	1	259	Mean Difference (IV, Fixed, 95% CI)	0.0 [‐0.04, 0.04]
6 Prothrombin index (% of normal)	1	50	Mean Difference (IV, Fixed, 95% CI)	‐2.30 [‐7.31, 2.71]
6.1 At 1‐7 days	1	50	Mean Difference (IV, Fixed, 95% CI)	‐2.30 [‐7.31, 2.71]
7 Coagulation factors II+ VII+ X (fraction of normal adult values)	1	269	Mean Difference (IV, Fixed, 95% CI)	0.01 [‐0.03, 0.05]
7.1 At 1‐7 days	1	269	Mean Difference (IV, Fixed, 95% CI)	0.01 [‐0.03, 0.05]